⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 8, 2026Ophthalmic Plastic and Reconstructive Surgery

Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Thyroid Eye Disease

Jawad Muayad Muhammad Z. Chauhan Leo M. Hall Akbar Shakoor Ahmed B. Sallam Imran Ahmed Amina Malik Robert C. Kersten

View at Publisher

Ask AI

Bookmark

Share

Key Points

To investigate the impact of GLP-1 receptor agonists on the risk of thyroid eye disease.
Matched cohort analysis
Comparison of GLP-1RA therapy to other glucose-lowering medications
Assessment of TED diagnoses, surgeries, and steroid use
GLP-1RA therapy associated with reduced risk of TED diagnoses
Lower rates of TED-related surgeries in patients using GLP-1RAs
Decreased systemic steroid use linked to GLP-1RA therapy

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Cohort analysis shows GLP-1RA therapy reduces thyroid eye disease risk in glucose-lowering treatments, suggesting protective effects.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Muayad et al. (2026) studied this question.

synapsesocial.com/papers/69d895796c1944d70ce067fd https://doi.org/10.1097/iop.0000000000003222

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis2024 · 12 citations
2Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – Clinical evidence and insightsCase Report · 2026
3Beyond Weight Loss: Association Between Glucagon-like peptide-1 Receptor Agonist Therapy and Incidence of Facial and Oculoplastic ProceduresOriginal Research · 2026 · 2 citations
4Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendationsHuman Clinical Trial · 2026 · 4 citations
5Beyond glycemic control: ocular effects of GLP-1 receptor agonists across medical and surgical ophthalmologyNarrative Review · 2026

Glucagon-Like Peptide-1 Receptor Agonists are Not Associated with an Increased Risk of Progressing to Vision-Threatening Diabetic Retinopathy2024
Glucagon-Like Peptide-1 Receptor Agonists and Ocular Outcomes: Metabolic Transition, Retinal Vulnerability, and Risk-Stratified Monitoring.2026
Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study2024
Parasitic Infections of the Lacrimal System: A Major Review of Etiology, Clinical Presentation, and ManagementOphthalmic Plastic and Reconstructive Surgery · 2026
Early Identification of Ecthyma Gangrenosum on the Eyelid MarginOphthalmic Plastic and Reconstructive Surgery · 2026

More from Ophthalmic Plastic and Reconstructive Surgery

More from Cornell University

More from University of Toronto

More from The University of Texas MD Anderson Cancer Center

More from University of Utah

More from University of Arkansas for Medical Sciences

More from Houston Methodist

More from Ain Shams University

More from Texas Medical Center

More from Methodist Hospital

More from Prism Eye Institute